Möchten Sie immer auf dem neuesten Stand bleiben?

Davos-Klosters, Switzerland, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Dr. Christina Rahm, Chief Formulator and Lead Scientist of The ROOT Brands, and Clayton Thomas, CEO, were invited to attend the 56th...

LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...

FORT LEE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...

GVN is is monitoring reports of a Nipah virus outbreak in India and emphasizes that such cases, while very concerning and serious, are not unexpected.

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March...

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March...

Delray Beach, FL, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The global drug device combination products market is projected to reach USD 379.17 billion by 2030, from USD 243.02 billion in 2025, at a CAGR of...

Company expects up to six-month review period per FDA guidelines  New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be...

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated...

South San Francisco, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- The California Institute for Regenerative Medicine (CIRM) has approved a new funding program to accelerate therapies for rare diseases,...